EPO

The EPO evidence base cited here is 7 sources — 3 clinical, 4 review. Its strongest evidence is human — 3 clinical studies, most recently 2022 ("Roxadustat Versus Epoetin Alfa for Treating Anemia in Patients with Chro…"). Regulatory status: FDA-approved (Epogen).

• Erythropoietin is the master regulator of red blood cell production; it signals through a homodimeric receptor to activate JAK2/STAT5, PI3K, and Ras/MAPK pathways in erythroid progenitors, driving their survival, proliferation, and terminal differentiation into hemoglobin-producing reticulocytes.
• A Phase III RCT in breast cancer patients receiving chemotherapy showed EPO completely prevented hemoglobin drops below 10 g/dL in the treatment arm (0% vs. 52% in controls), establishing erythropoiesis-stimulating agents (ESAs) as standard supportive care for chemotherapy-induced anemia.
• Newer oral HIF-PH inhibitors such as daprodustat demonstrated non-inferiority to injectable ESAs in dialysis patients in the landmark ASCEND-D NEJM trial (2021), with an oral route and reduced cardiovascular adverse signals compared to high-dose ESA therapy.

All citations link to the original source (PubMed, journal site, or regulatory filing). Independent research database — no vendor influence on what's cited.